Peptidylarginine deiminase activity in postmortem white matter of patients with multiple sclerosis

Neuroscience Letters

Volumn 260, Issue 1, 1999, Pages 74-76

  De Keyser, Jacques ^a   Schaaf, Margreet ^a   Teelken, Albert ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Multiple sclerosis; Myelin basic protein; Peptidylarginine deiminase; White matter

Indexed keywords

MYELIN BASIC PROTEIN; PROTEIN ARGININE DEIMINASE;

AGE; ARTICLE; AUTOPSY; BRAIN TISSUE; CONTROLLED STUDY; DEMYELINATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVOUS SYSTEM DEVELOPMENT; NEWBORN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WHITE MATTER;

AGED; CENTRAL NERVOUS SYSTEM; FEMALE; FETUS; GESTATIONAL AGE; HUMANS; HYDROLASES; INFANT, NEWBORN; MALE; MULTIPLE SCLEROSIS; POSTMORTEM CHANGES; PREGNANCY;

EID: 0033593458     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00947-1     Document Type: Article

References (15)

1. Chia L.S., Thompson J.E., Moscarello M.A. Alteration of lipid phase behavior in multiple sclerosis myelin revealed by wide angle x-ray diffraction. Proc. Natl. Acad. Sci. USA. 81:1984;1871-1874.
2. Encha-Razavi, F., Fetal neuropathology. In Duckett, S. (Ed.), Pediatric Neuropathology, Williams and Wilkins, Baltimore, MD, 1995, pp. 108-122.
3. Hogancamp W.E., Rodriguez M., Weinshenker B.G. The epidemiology of multiple sclerosis. Mayo Clin. Proc. 72:1997;871-878.
4. Lamensa J.W.E., Moscarello M.A. Deimination of human myelin basic protein by a peptidylarginine deiminase from bovine brain. J. Neurochem. 61:1993;987-996.
5. Martin R., Jaraquemada D., Flerlage M., Richert J., Whitaker J., Long E.O., McFarlin D.E., McFarland H.F. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis and healthy individuals. J. Immunol. 145:1990;540-548.
6. Mastronardi F.G., Ackerley C.A., Roots B.I., Moscarello M.A. Loss of myelin basic protein cationicity in DM20 transgenic mice is dosage dependent. J. Neurosci. Res. 44:1996;301-307.
7. Mastronardi F.G., Mak B., Ackerley C.A., Roots B.I., Moscarello M.A. Modifications of myelin basic protein in DM20 transgenic mice are similar to those in myelin basic protein from multiple sclerosis. J. Clin. Invest. 97:1996;349-358.
8. McLaurin J., Wee Yong V. Oligodendrocytes and myelin, Neurol. Clin. 13:1995;23-49.
9. Moscarello M.A., Wood D.D., Ackerley C., Boulias C. Myelin in multiple sclerosis is developmentally immature. J. Clin. Invest. 94:1994;146-154.
10. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83:1977;346-356.
11. Roth H.J., Kronquist E., Kerlero de Rosbo N., Crandall B.F., Campagnoni A.T. Evidence for the expression of four myelin basic protein variants in the developing human spinal cord. J. Neurosci. Res. 17:1987;321-328.
12. Trotter J.L., Pelfrey C.M., Trotter A.L., Selvidge J.A., Gushleff K.C., Mohanakumar T., McFarland H.F. T cell recognition of myelin proteolipid protein and myelin protelipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J. Neuroimmunol. 84:1998;172-178.
13. Wekerle H., Linington C., Lassmann H. Cellular immune reactivity within the CNS. Trends Neurosci. 9:1986;271-277.
14. Whitaker J.N., Mitchell G.W. A possible role for altered myelin basic protein in multiple sclerosis. Ann. Neurol. 40:1996;3-4.
15. Wood D.D., Moscarello M.A. The isolation, characterization, and lipid-aggregating properties of a citrulline containing basic myelin protein. J. Biol. Chem. 264:1989;5121-5127.